<p>Prasugrel is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows:</p>

<ul>
	<li>Patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI).</li>
	<li>Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI.</li>
</ul>